University of Leicester
Browse
Inclusion of multiple high‐risk hist.pdf (988.93 kB)

Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma

Download (988.93 kB)
journal contribution
posted on 2021-06-18, 15:13 authored by M Sereno, Z He, CR Smith, J Baena, M Das, RK Hastings, G Rake, DA Fennell, A Nakas, DA Moore, J Le Quesne
Aims: The decision to consider adjuvant chemotherapy (AC) for non-small cell lung cancer is currently governed by clinical stage. This study aims to assess other routinely collected pathological variables related to metastasis and survival for their ability to predict the efficacy of AC in lung adenocarcinoma. Methods and results: A retrospective single-centre series of 620 resected lung non-mucinous adenocarcinoma cases from 2005 to 2015 was used. Digital images of all slides were subjected to central review, and data on tumour histopathology, AC treatment and patient survival were compiled. A statistical case matching approach was used to counter selection bias. Several high-risk pathological criteria predict both pathological nodal involvement and early death: positive vascular invasion status (VI+) (HR = 2.10, P < 0.001), positive visceral pleural invasion status (VPI+) (HR = 2.16, P < 0.001), and solid/micropapillary-predominant WHO tumour type (SPA/MPPA) (HR = 3.29, P < 0.001). Crucially, these criteria also identify patient groups benefiting from AC (VI + HR = 0.69, P = 0.167, VPI + HR = 0.44, P = 0.004, SPA/MPPA HR = 0.36, P = 0.006). Cases showing VI+/VPI+/SPA/MPPA histology in the absence of AC stage criteria were common (170 of 620 total), and 8 had actually received AC. This group showed much better outcomes than equivalent untreated cases in matched analysis (3-year OS 100.0% versus 31.3%). Inclusion of patients with VI+/VPI+/SPA/MPPA histology would increase AC-eligible patients from 51.0% to 84.0% of non-mucinous tumours in our cohort. Conclusions: Our data provide preliminary evidence that the consideration of AC in patients with additional high-risk pathological indicators may significantly improve outcomes in operable lung adenocarcinoma, and that AC may be currently underused. [Description sourced from journal publisher version of record].

Funding

Medical Research Council. Grant Number: RG94521

History

Citation

Sereno, M, He, Z, Smith, C R, Baena, J, Das, M, Hastings, R K, Rake, G, Fennell, D A, Nakas, A, Moore, D A & Le Quesne, J (2021) Histopathology 78, 838– 848. https://doi.org/10.1111/his.14301 Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma

Author affiliation

Leicester Cancer Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust

Version

  • VoR (Version of Record)

Published in

Histopathology

Volume

78

Issue

6

Pagination

838 - 848

Publisher

Wiley

issn

0309-0167

eissn

1365-2559

Acceptance date

2020-11-04

Copyright date

2020

Available date

2021-06-18

Language

eng

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC